Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag
Published on November 4, 2021
Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.